Rated for year 2017: Vegan non compliant

Score: -1

Industry: Pharmaceuticals



Pharmaceuticals industry. Sanofi does animal testing: “We are sometimes required to use animals to test our products in the development phase and our vaccines before distributing them” (p 11 of 2016 20-F report).

Among positive points, we appreciate that in February 2017 Sanofi has committed to stop animal testing and killing in the case of training sessions for sales (see PETA’s source). Furthermore, the number of tested animals has decreased by 7.6% from 2015 to 2016 (see sources).

However, we regret that the amount is still tremendous, nearly half million animals (464,696 exactly) are tested by SANOFI in 2016 (see sources). Most of them are killed after experimentation (we are asking for more precise statistics on the number of rehabilitations and other metrics to Sanofi’s chief veterinary officer).

Moreover, Sanofi maintains its animal testing policy and acknowledges its dependence to regulations and third-parties to commercialize its products: “Testing on animals can be vital for the development or commercialization of a product. If applicable regulations were to ban this practice, or if, due to pressure from animal welfare groups, we were no longer able to source animals to perform such tests, it would be difficult and in some cases impossible to develop or distribute our products in certain jurisdictions under the applicable marketing authorizations. In addition, negative publicity regarding our use, or the industry’s use, of animal subjects could harm our reputation. We rely on third parties for the discovery, manufacture and marketing of some of our product” (p 11 of 2016 20-F report).

The Vegan position and scientific studies assert that even slight differences between human and animal genes are enough to induce errors in drugs design, that animal modeling (and testing) can be replaced by computer modeling and in vitro testing (see PETA link), as innovative solutions as synthetic liver (e.g. biomimiks) and in vitro lung (e.g. epithelix) in order to test diseases, drugs and chemical substances.

Therefore, we regret that Sanofi does not work significantly towards legislation improvements to stop unnecessary massive animal testing, suffering and killing. Moreover, as far as the company keeps on experimenting on animals, regarding useless massive animal suffering and the need of transparency to vegan investors, we regret that SANOFI has not disclosed metrics as the number of animals tested, killed or saved and rehabilitated (total and per species) in the 2016 annual reports (registration document and US 20-F).

Furthermore, SANOFI supports the animal industries, through its “Animal Health” business line, which provides drugs and vaccines to pets and livestock. The animal business represents 2.7 billion euros, among which 546 million for the fipronil, a controversial and toxic insecticide (p 140 of 2016 registration document).

Few actions for biodiversity are mentioned in the annual report: no animals nor plants from CITES list are used in the production process (p376 2016 registration document).

BENEFICIAL ASPECTS: stop animal testing for sales training

HARMFUL ASPECTS: animal testing and business support to animal industries and non disclosure of detailed metrics on animal testing



SANOFI 2016 registration document (only in French)

SANOFI 2016 US SEC Form 20-F



Biomimiks: synthetic liver to test diseases, drugs and chemical substances

Epithelix: in vitro lung to test diseases, drugs and chemical substances